Diagnosis and management of pituitary tumors: Recent advances

Primary Care - Clinics in Office Practice

Volumn 30, Issue 4, 2003, Pages 765-789

  Pickett, Cheryl A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXAPINE; ANGIOPEPTIN; BROMOCRIPTINE MESILATE; BUTYROPHENONE DERIVATIVE; CABERGOLINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOTROPIN; ESTROGEN; FLUOXETINE; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; METHYLDOPA; MONOAMINE OXIDASE INHIBITOR; OCTREOTIDE; PEGVISOMANT; PERGOLIDE; PERGOLIDE MESILATE; PHENOTHIAZINE DERIVATIVE; PROLACTIN; QUINAGOLIDE; RESERPINE; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; TRICYCLIC ANTIDEPRESSANT AGENT;

CANCER RADIOTHERAPY; CLINICAL EXAMINATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSECTOMY; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROLACTINOMA; PSYCHOSIS; RETROPERITONEAL FIBROSIS; REVIEW; TREATMENT PLANNING;

EID: 0347694849     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00094-0     Document Type: Review

References (81)

1. Elster A. Modern imaging of the pituitary. Radiology 1993;187:1-14.
2. Molitch ME, Russell EJ. The pituitary incidentaloma. Ann Intern Med 1990;112:925-31.
3. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994;112:817-20.
4. Annegers JF, Coulam CB, Abboud CF, Laws ER, Kurland LT. Pituitary adenoma in Olmstead County, Minnesota, 1935-1977. A report of an increasing incidence of diagnosis in women of childbearing age. Mayo Clinic Proc 1978;53:641-3.
5. Kurland LT, Schoenber BS, Annegers JF, Okazaki H, Molgaard CA. The incidence of primary intracranial neoplasms in Rochester, Minnesota, 1935-1977. Ann NY Acad Sci 1982;381:6-16.
6. Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999;28:81-117.
7. Freda PU, Wardlaw SL, Post KD. Extensive personal experience: unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab 1996;81:3455-9.
8. Webster J. Clinical management of prolactinomas. Best practice and research. J Clin Endocrinol Metab 1999;13:395-408.
9. Molitch ME. Prolactinoma. In: Melmed S, editor. The pituitary. Cambridge, MA: Blackwell Science Inc. 1995. p. 443-7.
10. Tyson JE, Hwang P, Goyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972;113:652-5.
11. Stern JM, Konner M, Herman TN, Reichlin S. Nursing behavior, prolactin and postpartum amenorrhoea during prolonged lactation in American and!Kung mothers. Clin Endocrinol 1986;25:247-58.
12. Noel GL, Suh HK, Frantz AG. Prolactin release during nuring and breast stimulation in postpartum and nonpostpartum subjects. J Clin Endocrinol Metab 1974;38:413-43.
13. Molitch ME. Medical treatment of prolactinomas. In: Molitch ME. editor. Advances in pituitary tumor therapy, vol. 28. Endocrinology and metabolism clinics of North America. Philadelphia, PA: W.B. Saunders Co. 1999. p. 143-69.
14. Cavaco B, Prazeres S, Santos MA, Sobrinho LG, Leite V. Hyperprolactinemia due to big prolactin is differently detected by commercially available immunoassays. J Endocrinol Invest 1999;22:203-8.
15. Fahie Wilson MN, Soule SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34:252-8.
16. Rubin RT, Hays SE. The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 1980:5:121-37.
17. Stears JC. Imaging of the sella and perisellar region. In: Wierman ME, editor. Diseases of the pituitary. vol. 3. Contempory endocrinology. Totowa, NJ: Humana Press. 1997. p. 323-59.
18. Mbanya JC, Mendelow AD, Crawford PJ, Hall K, Dewar JH, Kendall-Taylow P. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas. Br J Neurosurg 1993;7:510-27.
19. Moster ML, Savino PJ, Schatz NJ, Snyder PJ, Sergott RC, Bosley TM. Visual function in prolactinoma patients treated with bromocriptine. Ophthalmology 1985;92:1332-41.
20. Jasonni VM, Rafalli R, de March A, et al. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstst Gynecol Scand 1991;70:493-5.
21. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP, et al. Long-term treatment of prolactin-secreting macroadenoma with pergolide. J Clin Endocrinol Metab 2000;856:8-13.
22. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G. et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists in the treatment of prolactinomas. Clin Endocrinol 2000;53:549-50.
23. Duranteau L, Chanson P, Lavoinne A, et al. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine resistant prolactinomas. Clin Endocrino 1991:34:25-9.
24. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al. Prolactinomas resistant to standard doamine agonists respond to chronic cabergoline. J Clin Endocrinol Metab 1997;82:2755-66.
25. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, et al. Cabergoline treatment rapidly improves gonaldal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998;138:286-93.
26. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 1997;46:409-13.
27. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolacinaemia and inhibition of lactation. Drug Saf 1996;14:228-38.
28. Montini M, Pagani G, Gianola D, et al. Long-lasting supression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine. J Clin Endocrinol Metab 1986;63:266-8.
29. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-40.
30. Molitch ME. Pregnancy and hyperprolacinemic women. N Engl J Med 1985;312:1365-70.
31. Turner HE, Adams CB, Wass J. Transsphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists? Eur J Endocrinol 1999;140:43-7.
32. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson C. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999;44:254-61.
33. Di Sarno A, Colao A, Di Somma C, Pivonello R, Milano N, Auriemma R, et al. Effect of long-term cabergoline withdrawal on tumor mass, PRL levels and clinical symptoms in prolactinomas. [Abstract OR 13-1] Endocrine Society Meeting. San Francisco, 2002.
34. Luizzi A, Dallabonzana D, Giuseppe MD, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656-9.
35. Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin C. N Engl J Med 1979;301:1138-42.
36. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, et al. Preoperative treatment of acromegaly with long acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040-8.
37. Costa ACF, Rossi A, Martinelli Jr. CE, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002;87:3142-7.
38. Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res 2000;53:71-5.
39. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-9.
40. Osman IA, James RA, Chatterjee S, Mathias D, Kendall-Taylor P. Factors determining the long-term outcome of surgery for acromegaly. Am J Med 1994;87:617-23.
41. Rajasoorya C, Holdaway M, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102.
42. Swearingen B, Barker FG, Katznelson L, Biller B, Grinspoon S, Klinbanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
43. Abosch A, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411-8.
44. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85:4596-602.
45. Kreutzer J, Vance ML, Lopes MB, Laws ERJ. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern criteria. J Clin Endocrinol Metab 2001;86:4072-7.
46. Kristof RA, Stoffel-Wagner B, Klingmuller D, Schramm J. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir 1999;141:399-405.
47. Wasko R, Ruchala M, Sawicka J, Kotwicka M, Liebert W, Sowinski J. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest 2000;23:12-8.
48. Nienke R, Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85:2476-82.
49. Jackson IM, Noren G. Role of gamma knife radiosurgery in acromegaly. Pituitary 1999;2:71-7.
50. Marcou Y, Plowman PN. Stereotactic radiosurgery for pituitary adenomas. Trends Endocrinol Metab 2000;11:132-7.
51. Vance ML. Gamma knife radiotherapy for pituitary adenomas. The Endocrine Society 84th Annual Meeting. San Francisco, CA; 2002. p. S9-2.
52. Melmed S. Acromegaly. N Engl J Med 1990;322:966-77.
53. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999;141:267-71.
54. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol 2002;56:65-71.
55. Heijckmann CA, Menheere PP, Sels JP, Beuls EA, Wolfffenbuttel BH. Clinical experience with Sandostatin LAR in patients with acromegaly. Neth J Med 2001;59:286-91.
56. Davies PH, Stewart SE, Lacranjan J, Sheppard MG, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311-6.
57. Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol 2001;55:411-5.
58. Neal JM. Successful pregnancy in a woman with acromegaly treated with octreotide. Endocr Pract 2000;6:148-50.
59. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001;8:287-305.
60. Abs R, Verhels J, Master D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8.
61. Parkinson C, Trainer PJ. Growth hormone receptor antagonists therapy for acromegaly. Best ractice and research. J Clin Endocrinol Metab 1999;83:1163-7.
62. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonis pegvisomant. N Engl J Med 2000;342:1171-7.
63. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Markan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;38:1754-9.
64. Parkinson C, Trainer PJ. The place of pegvisomant in the mangement of acromegaly. Exp Opin Investig Drugs 2001;10:1725-35.
65. Melmed S. Acromegaly. In: Melmed S, editor. Pituitary tumors. Cambridge, MA: Blackwell Sciences. 1995. p. 413-42.
66. Weiss V, Sonka K, Pretl M, Dostalova S, Klozar J, Rambousek P, et al. Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest 2000;23:515-9.
67. Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999;84:3859-66.
68. Katnelson L, Alexander JM, Klibanski A. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993;76:1089-94.
69. Turner HE, Adams CBT, Wass JAH. Pituitary tumours in the elderly: a 20 year experience. Eur J Endocrinol 1999;140:383-9.
70. Turner HE, Stratton IM, Byrne JV, Adams CB, Wass JA. Audit of selected patients with nonfunctioning pituitary adenomas without irradiation - a follow-up study. Clin Endocrinol 1999;51:281-4.
71. Shomali ME, Katznelson L. Medical therapy for gonadotroph and thyrotroph tumors. In: Molitch ME, editor. Advances in pituitary tumor therapy. vol. 28:1. Endocrinology and metabolism clinics of North America. Philadelphia, PA: W.B. Saunders Co. 1999.
72. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, et al. New medical approaches in pituitary adenomas. Horm Res 2000;53:76-87.
73. Samuels MH. Thyrotropin-secreting pituitary tumors: differential diagnosis and treatment. In: Wierman ME, editor. Diseases of the Pituitary: diagnosis and treatment, contemporary endocrinology. Totowa, NJ: Humana Press. 1997. p. 295-304.
74. McCutcheon IE, Weintraub BD, Oldfield EH. Surgical treatment of thyrotropin-secreting pituitary sdenomas. J Neurosurg 1990;73:674-83.
75. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-38.
76. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-40.
77. Fukuda T, Yokoyama N, Tamai M, Imaizumi M, Kimura H, Tominaga T, et al. Thyrotropin secreting pituitary adenoma effectively treated with octreotide. Intern Med 1998;37:1027-30.
78. Caron P, Arlot S, Bauter C, Chanson P, Kuhn JM, Pugeat M, et al. Efficacy of the long-acting octrotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:2849-53.
79. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 1994;40:421-8.
80. Lee EJ, Jameson JL. Gonadotropin (FSH and LH) pituitary tumors. In: Wierman ME, editor. Diseases of the pituitary, contemporary endocrinology. Totowa, NJ: Humana Press. 1997. p. 247-72.
81. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary tumors. Clin Endocrinol (Oxf) 1994,41:359-64.